Eli Lilly and Company (LLY)

NYSE: LLY · IEX Real-Time Price · USD
-4.88 (-0.55%)
At close: Jun 14, 2024, 4:00 PM
+1.19 (0.14%)
After-hours: Jun 14, 2024, 7:58 PM EDT
Market Cap 834.88B
Revenue (ttm) 35.93B
Net Income (ttm) 6.14B
Shares Out 950.41M
EPS (ttm) 6.79
PE Ratio 129.37
Forward PE 63.22
Dividend $5.20 (0.59%)
Ex-Dividend Date May 15, 2024
Volume 1,982,924
Open 882.33
Previous Close 883.33
Day's Range 876.00 - 884.61
52-Week Range 434.34 - 885.06
Beta 0.36
Analysts Strong Buy
Price Target 798.15 (-9.14%)
Earnings Date Aug 6, 2024

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]

Sector Healthcare
Founded 1876
Employees 43,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $798.15, which is a decrease of -9.14% from the latest price.

Price Target
(-9.14% downside)
Analyst Consensus: Strong Buy
Stock Forecasts


GLP-1 weight-loss drugs: Analyst discusses what investors should know

GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter join...

Other symbols: NVO
22 hours ago - Yahoo Finance

A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL

The use of artificial intelligence across biopharma and life science tools and services is developing quickly. Will A.I. become a major disruptive technology in healthcare with the potential to signif...

Other symbols: AMGNCRLTMO
23 hours ago - Schwab Network

These 4 S&P 500 stocks are helping to tame U.S. market volatility

Far from being a source of concern, the U.S. stock market's extremely low volatility is something to celebrate. The CBOE Volatility Index VIX, or VIX, which is a measure of the S&P 500's SPX expected ...

Other symbols: JPMXOM
1 day ago - Market Watch

Jim Cramer looks at Eli Lilly's outlook as the company's Alzheimer drug goes through FDA

'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.

3 days ago - CNBC Television

Eli Lilly may have developed the greatest drug of all time, says Jim Cramer

'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.

3 days ago - CNBC Television

Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug

Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, CNBC's Jim Cramer said the company's new Alzheimer's treatment has the potential to further...

3 days ago - CNBC

Eli Lilly closer to securing FDA approval for Alzheimer's drug

Eli Lilly (LLY) is one step closer to getting its new Alzheimer's treatment approved by the Food and Drug Administration (FDA) after a panel voted to recommend its use. BMO Capital Markets Managing Di...

3 days ago - Yahoo Finance

Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst

BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company LLY, with a price forecast of $1,000.

3 days ago - Benzinga

Top 4 Health Care Stocks That May Keep You Up At Night This Month

As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: APLTINSMTMDX
4 days ago - Benzinga

Dr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first time

Dr. Howard Fillit, Alzheimer's Drug Discovery Foundation co-founder and chief science officer, joins 'Squawk Box' to discuss news of FDA panel's approval of Eli Lilly's Alzheimer's drug Donanemab, the...

4 days ago - CNBC Television

Morning Minute: Tuesday, June 11

Apple (AAPL) announces new A.I. initiatives, Eli Lilly (LLY) stock is on the move after its Alzheimer's drug gets positive news and Alphabet (GOOGL) receives positive analyst notes.

Other symbols: AAPLGOOGL
4 days ago - Schwab Network

Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab

Eli Lilly (LLY) shares gained more than 2% in extended trading on Monday after a panel of independent advisors to the Food and Drug Administration (FDA) unanimously recommended the pharmaceutical gian...

4 days ago - Investopedia

Alzheimer's could be a ‘very big category' for Eli Lilly: former FDA commissioner

Alzheimer's could eventually be a “very big category” for Eli Lilly & Co (NYSE: LLY), says Dr Scott Gottlieb. He's the former commission of the U.S. Food & Drug Administration.

4 days ago - Invezz

FDA Panel Unanimously Recommends Eli Lilly's Alzheimer's Drug

A Food and Drug Administration advisory panel unanimously voted Monday to recommend Eli Lilly's Alzheimer's drug donanemab for approval, according to multiple outlets, sending the pharmaceutical compa...

4 days ago - Forbes

FDA advisers say Eli Lilly Alzheimer's treatment is effective

Dr. Scott Gottlieb, Former FDA Commissioner, joins 'Closing Bell Overtime' to talk news that the FDA has deemed Eli Lilly's Alzheimers treatment as effective.

4 days ago - CNBC Television

Eli Lilly exec expects obesity pill data in April 2025

Data from Eli Lilly's late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly executive said on Monday.

4 days ago - Reuters

Eli Lilly's Alzheimer's drug gets backing from FDA advisers

Eli Lilly & Co.'s experimental Alzheimer's drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Adminis...

4 days ago - Market Watch

Eli Lilly exec says seeing out of pocket payments for obesity drug in US

A top Eli Lilly executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.

4 days ago - Reuters

FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval

A panel of independent advisors to the FDA recommended Eli Lilly's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If approved, Eli L...

4 days ago - CNBC

FDA advisers say Eli Lilly's Alzheimer's treatment is effective

CNBC's Angelica Peebles joins 'Closing Bell' to discuss the FDA's advisers vote on Eli Lilly's Alzheimer's drug.

4 days ago - CNBC Television

Eli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared Holz

Jared Holz, Mizuho Securities healthcare equity strategist, joins 'Squawk Box' to discuss the FDA's review of Eli Lilly's experimental Alzheimer drug, whether the drug is a game changer, and more.

5 days ago - CNBC Television

US FDA advisers to review Eli Lilly Alzheimer's drug

An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's experimental Alzheimer's drug donanemab.

5 days ago - Reuters

Eli Lilly's Alzheimer's Drug Donanemab Is Being Considered For FDA Approval—Here's What To Know

A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly's experimental Alzheimer's drug donanemab for FDA approval, a closely watched decision that could pave ...

5 days ago - Forbes

Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine INDIANAPOLIS , June 8, 2024...

7 days ago - PRNewsWire

Up 400% In 3 Years, Eli Lilly Stock Just Keeps Giving

Eli Lilly stock (NYSE: LLY) has seen phenomenal gains of 400% from levels of $170 in early 2021 to around $840 now. This reflects a meaningful outperformance compared to some of its peers, with Pfizer...

8 days ago - Forbes